Evidence map›Paper›PMID 26935038›Full record

ReviewNature reviews. Cardiology2016

Epidemiology and aetiology of heart failure.

Boback Ziaeian, Gregg C Fonarow

3 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Cardiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 960 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
960citing papers in PubMed, 10 pooled it
60.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04307823 nacompletednot on this mapstarted 2019, after this paper: background citation

Effects of Respiratory Muscles Training on Cardiopulmonary Parameters and Quality of Life in Patients With Dilated Cardiomyopathy

TypeinterventionalSponsorRiphah International UniversityRan2019 to 2020Enrolled22ConditionsDilated CardiomyopathyArmsTreadmill training, Treadmill protocol and Respiratory training
NCT04592445 narecruitingnot on this mapstarted 2020, after this paper: background citation

Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having Heart Failure With Preserved Ejection Fraction: Randomized Controlled Feasibility Trial - The Rebalance HF Study

TypeinterventionalSponsorAxon Therapies, Inc.Ran2020 to 2029Enrolled150ConditionsHeart Failure With Preserved Ejection Fraction (HFpEFArmsGreater Splanchnic Nerve Ablation, Sham Control
NCT04696120 phase2unknown statusnot on this mapstarted 2021, after this paper: background citation

Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial

TypeinterventionalSponsorKorea University Guro HospitalRan2021 to 2023Enrolled200ConditionsHeart Failure, Sinus Rhythm, Cerebrovascular DiseaseArmsApixaban, Placebo
3 · Its place in the literature

Who cites it

960 citing papers in PubMed, 10 syntheses or guidelines pooled it, 1,859 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

900 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Boback ZiaeianDivision of Cardiology, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, California 90095, USA.
Gregg C FonarowDivision of Cardiology, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, California 90095, USA.
University of California, Los Angeles · US

Funding

CARDIOVASCULAR SCIENTIST TRAINING PROGRAMT32HL007895 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHIVKUMAR, KALYANAM, WATSON, KAROL E · 1998 to 2023
$9.2M
NHLBI NIH HHS T32 HL007895
6 · The paper itself

Abstract

Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience numerous symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance, and fluid retention. Although the underlying causes of HF vary according to sex, age, ethnicity, comorbidities, and environment, the majority of cases remain preventable. HF is associated with increased morbidity and mortality, and confers a substantial burden to the health-care system. HF is a leading cause of hospitalization among adults and the elderly. In the USA, the total medical costs for patients with HF are expected to rise from US$20.9 billion in 2012 to $53.1 billion by 2030. Improvements in the medical management of risk factors and HF have stabilized the incidence of this disease in many countries. In this Review, we provide an overview of the latest epidemiological data on HF, and propose future directions for reducing the ever-increasing HF burden.

Indexed as

Cost of IllnessHealth Care CostsHeart FailureHumansIncidencePrevalenceRisk Factors

Identifiers

PMID26935038
PMCPMC4868779
OpenAlexW2292493149

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.